Rep. Buddy Carter on Trump's Budget, Energy Policy, and Pharmaceutical Independence

Trump's 2026 Budget Proposal

• 🎯 The Trump administration has released a "skinny" 2026 budget proposal with a top-line of approximately $1.7 trillion, covering non-defense and defense spending.
• 💡 The budget aims to bring back energy dominance and control government spending, contrasting with the Biden administration's approach.
• ⚠️ The proposal excludes spending related to Medicare and Medicaid, with efforts focused on stabilizing and sustaining these programs.

Tax Policy and Economic Growth

• 💰 Congressman Carter supports a "one big beautiful bill" approach that combines tax policy and budget considerations to prevent the largest tax increase in history.
• 📈 He argues that extending the tax cuts implemented during the previous administration can lead to a booming economy and increased government revenue, citing a 48% revenue increase after 2017 tax reductions.
• 🤝 Carter respectfully disagrees with proposals for separate bills, advocating for a unified approach to tax extensions.

Energy Tax Credits and Market-Driven Solutions

• ⚡ While not voting for the Inflation Reduction Act (IRA), Carter suggests a nuanced approach to its energy tax credits, advocating for a scalpel rather than a sledgehammer.
• 💡 He believes that parts of the IRA that stabilize supply chains and promote domestic manufacturing might be worth retaining.
• 🚫 Carter opposes government picking "winners and losers" in the energy sector, emphasizing that such interventions lead to consumer losses and that the market should drive these decisions.

Pharmaceutical Independence

• 🇺🇸 Carter highlights the concern that 80% of generic medicines are made or partially made in China, launching the American-made medicines caucus to address this.
• 🏥 He stresses the need for pharmaceutical independence, drawing parallels to energy independence, especially after the pandemic revealed reliance on adversaries.
• 🚀 The caucus aims to incentivize companies to bring pharmaceutical manufacturing back to the U.S. through domestic incentives and shifting away from overseas production.